Nasal Polyposis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasal Polyposis - Pipeline Review, H2 2017, provides an overview of the Nasal Polyposis (Ear Nose Throat Disorders) pipeline landscape. Nasal polyps (NP) are non cancerous growths within the nose or sinuses. Symptoms include runny nose, snoring, itchiness, persistent stuffy, facial pain, loss of taste. Risk factors include asthma, cystic fibrosis, Churg-Strauss syndrome and allergic fungal sinusitis. Treatment includes corticosteroids, antihistamines to treat allergies and antibiotics to treat a chronic or recurring infection. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasal Polyposis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Nasal Polyposis (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Nasal Polyposis (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasal Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Phase II stages are 1, 1 and 3 respectively. Nasal Polyposis (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Nasal Polyposis (Ear Nose Throat Disorders). - The pipeline guide reviews pipeline therapeutics for Nasal Polyposis (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Nasal Polyposis (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Nasal Polyposis (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Nasal Polyposis (Ear Nose Throat Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Nasal Polyposis (Ear Nose Throat Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Nasal Polyposis (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Nasal Polyposis - Overview Nasal Polyposis - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Nasal Polyposis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Nasal Polyposis - Companies Involved in Therapeutics Development Cumberland Pharmaceuticals Inc F. Hoffmann-La Roche Ltd OptiNose US Inc Regeneron Pharmaceuticals Inc Nasal Polyposis - Drug Profiles AK-001 - Drug Profile Product Description Mechanism Of Action R&D Progress dupilumab - Drug Profile Product Description Mechanism Of Action R&D Progress fluticasone propionate - Drug Profile Product Description Mechanism Of Action R&D Progress ifetroban sodium - Drug Profile Product Description Mechanism Of Action R&D Progress omalizumab - Drug Profile Product Description Mechanism Of Action R&D Progress Nasal Polyposis - Dormant Projects Nasal Polyposis - Product Development Milestones Featured News & Press Releases Feb 09, 2017: Michael F. Marino Joins OptiNose as Chief Legal Officer Jan 31, 2017: OptiNose Announces FDA Acceptance for Filing of the New Drug Application for OPN-375 Jan 26, 2017: OptiNose Appoints Keith Goldan as Chief Financial Officer Sep 29, 2016: Tom Gibbs Joins OptiNose as Chief Commercial Officer Sep 08, 2016: Allakos Initiates Phase 2 Trial of AK001 in Patients with Nasal Polyposis Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association Sep 24, 2015: OptiNose Announces Positive Results of Second Phase III Pivotal Trial for OPN-375 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Nasal Polyposis, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Nasal Polyposis - Pipeline by Cumberland Pharmaceuticals Inc, H2 2017 Nasal Polyposis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 Nasal Polyposis - Pipeline by OptiNose US Inc, H2 2017 Nasal Polyposis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 Nasal Polyposis - Dormant Projects, H2 2017
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.